Loading...

INSYS Therapeutics

DB:NPR1
Snowflake Description

High growth potential with mediocre balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
NPR1
DB
$320M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Insys Therapeutics, Inc., a specialty pharmaceutical company, focuses on cannabinoids and drug delivery systems that address unmet patient needs. The last earnings update was 36 days ago. More info.


Add to Portfolio Compare Print
  • INSYS Therapeutics has significant price volatility in the past 3 months.
NPR1 Share Price and Events
7 Day Returns
-6.2%
DB:NPR1
-0.7%
DE Biotechs
2.5%
DE Market
1 Year Returns
-
DB:NPR1
-9.2%
DE Biotechs
-6.7%
DE Market
NPR1 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
INSYS Therapeutics (NPR1) -6.2% -10.9% -4.2% - -71.9% -74.8%
DE Biotechs -0.7% 4.7% -6.2% -9.2% 44% 8.7%
DE Market 2.5% 3.3% 9.2% -6.7% 9% 13.5%
1 Year Return vs Industry and Market
  • No trading data on NPR1.
  • No trading data on NPR1.
Price Volatility
NPR1
Industry
5yr Volatility vs Market

NPR1 Value

 Is INSYS Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether INSYS Therapeutics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as INSYS Therapeutics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for INSYS Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is €3.85.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for INSYS Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are INSYS Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:NPR1 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-1.68
NasdaqGM:INSY Share Price ** NasdaqGM (2019-04-18) in USD $4.21
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.53x
Germany Market PE Ratio Median Figure of 421 Publicly-Listed Companies 19.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of INSYS Therapeutics.

DB:NPR1 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:INSY Share Price ÷ EPS (both in USD)

= 4.21 ÷ -1.68

-2.5x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • INSYS Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • INSYS Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does INSYS Therapeutics's expected growth come at a high price?
Raw Data
DB:NPR1 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.5x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
52.5%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for INSYS Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on INSYS Therapeutics's assets?
Raw Data
DB:NPR1 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $-0.58
NasdaqGM:INSY Share Price * NasdaqGM (2019-04-18) in USD $4.21
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.85x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:NPR1 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:INSY Share Price ÷ Book Value per Share (both in USD)

= 4.21 ÷ -0.58

-7.27x

* Primary Listing of INSYS Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • INSYS Therapeutics has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.

Next steps:

  1. Take a look at INSYS Therapeutics's forecasted future earnings and revenues from industry analysts to understand how the company is expected to perform in the future against its competitors and the wider market.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through INSYS Therapeutics's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Biotechs industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess INSYS Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. INSYS Therapeutics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

NPR1 Future Performance

 How is INSYS Therapeutics expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
52.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is INSYS Therapeutics expected to grow at an attractive rate?
  • INSYS Therapeutics's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • INSYS Therapeutics's earnings growth is expected to exceed the Germany market average.
  • INSYS Therapeutics's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:NPR1 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:NPR1 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 52.5%
DB:NPR1 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 23.7%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.4%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:NPR1 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:NPR1 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 250 50 68 2
2022-12-31 185 14 10 2
2021-12-31 112 -22 -41 4
2020-12-31 79 -48 -74 4
2019-12-31 60 15 -86 5
DB:NPR1 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 82 -56 -125
2018-09-30 97 -60 -125
2018-06-30 110 -73 -261
2018-03-31 129 -61 -242
2017-12-31 141 -61 -227
2017-09-30 164 -25 -185
2017-06-30 191 23 -15
2017-03-31 218 30 -1
2016-12-31 242 59 8
2016-09-30 281 61 29
2016-06-30 312 78 51
2016-03-31 323 98 54

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • INSYS Therapeutics's earnings are expected to grow significantly at over 20% yearly.
  • INSYS Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:NPR1 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from INSYS Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:NPR1 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.71 0.71 0.71 1.00
2022-12-31 0.11 0.11 0.11 1.00
2021-12-31 -0.45 -0.45 -0.45 1.00
2020-12-31 -0.88 -0.88 -0.88 1.00
2019-12-31 -0.86 -0.34 -1.55 4.00
DB:NPR1 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -1.68
2018-09-30 -1.71
2018-06-30 -3.57
2018-03-31 -3.33
2017-12-31 -3.12
2017-09-30 -2.56
2017-06-30 -0.21
2017-03-31 -0.02
2016-12-31 0.11
2016-09-30 0.41
2016-06-30 0.71
2016-03-31 0.76

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if INSYS Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess INSYS Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
INSYS Therapeutics has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

NPR1 Past Performance

  How has INSYS Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare INSYS Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • INSYS Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare INSYS Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare INSYS Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
INSYS Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from INSYS Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:NPR1 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 82.08 -124.51 123.75 56.09
2018-09-30 97.21 -125.32 118.80 58.09
2018-06-30 109.53 -261.03 115.07 63.16
2018-03-31 128.64 -241.86 114.68 62.28
2017-12-31 140.69 -226.84 116.44 62.95
2017-09-30 164.07 -184.56 118.97 62.06
2017-06-30 191.17 -15.44 124.75 59.03
2017-03-31 217.82 -1.22 127.95 67.81
2016-12-31 242.28 7.59 131.74 73.91
2016-09-30 281.33 29.38 142.81 74.50
2016-06-30 312.07 51.09 140.30 70.31
2016-03-31 323.05 54.48 143.95 65.21
2015-12-31 330.32 58.05 143.62 56.78
2015-09-30 299.89 47.34 134.82 53.64
2015-06-30 269.65 34.21 128.87 48.34
2015-03-31 245.15 34.26 116.36 39.73
2014-12-31 219.09 36.05 102.39 33.14
2014-09-30 195.81 52.73 88.22 23.37
2014-06-30 166.74 52.81 74.62 18.09
2014-03-31 129.87 47.89 58.97 10.82
2013-12-31 99.29 40.38 45.57 8.50
2013-09-30 64.25 9.20 33.91 6.01
2013-06-30 39.79 -6.63 26.83 5.39
2013-03-31 24.51 -17.55 22.48 5.16
2012-12-31 15.48 -24.38 19.58 6.31
2012-09-30 10.32 -17.88 17.03 8.60
2012-06-30 5.57 -13.91 13.10 9.06

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if INSYS Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if INSYS Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if INSYS Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess INSYS Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
INSYS Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

NPR1 Health

 How is INSYS Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up INSYS Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • INSYS Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • INSYS Therapeutics's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of INSYS Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • INSYS Therapeutics has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from INSYS Therapeutics Company Filings, last reported 3 months ago.

DB:NPR1 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 -43.10 0.00 95.68
2018-09-30 0.14 0.00 100.56
2018-06-30 24.64 0.00 104.90
2018-03-31 47.36 0.00 114.44
2017-12-31 66.21 0.00 117.19
2017-09-30 106.02 0.00 121.65
2017-06-30 266.38 0.00 141.62
2017-03-31 267.79 0.00 155.29
2016-12-31 269.59 0.00 182.88
2016-09-30 270.72 0.00 169.65
2016-06-30 258.46 0.00 158.37
2016-03-31 247.50 0.00 163.63
2015-12-31 252.31 0.00 159.09
2015-09-30 236.61 0.00 155.47
2015-06-30 203.96 0.00 115.28
2015-03-31 184.63 0.00 101.46
2014-12-31 165.67 0.00 82.86
2014-09-30 144.96 0.00 62.83
2014-06-30 121.53 0.00 54.74
2014-03-31 97.30 0.00 46.92
2013-12-31 79.48 0.00 45.38
2013-09-30 47.57 0.00 31.35
2013-06-30 34.19 0.00 21.75
2013-03-31 -63.48 70.38 0.69
2012-12-31 -64.68 70.24 0.36
2012-09-30
2012-06-30
  • INSYS Therapeutics has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if INSYS Therapeutics's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • INSYS Therapeutics has sufficient cash runway for 1.5 years based on current free cash flow.
  • INSYS Therapeutics has sufficient cash runway for 1.3 years if free cash flow continues to grow at historical rates of 109.1% each year.
X
Financial health checks
We assess INSYS Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. INSYS Therapeutics has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

NPR1 Dividends

 What is INSYS Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from INSYS Therapeutics dividends.
If you bought €2,000 of INSYS Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate INSYS Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate INSYS Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:NPR1 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:NPR1 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as INSYS Therapeutics has not reported any payouts.
  • Unable to verify if INSYS Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of INSYS Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as INSYS Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess INSYS Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can INSYS Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. INSYS Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

NPR1 Management

 What is the CEO of INSYS Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Andy Long
COMPENSATION $1,202,863
TENURE AS CEO 0 years
CEO Bio

Mr. Andrew G. Long, also known as Andy, has been Chief Executive Officer of INSYS Therapeutics, Inc. since April 15, 2019. He served as Chief Financial Officer of INSYS Therapeutics, Inc. since August 07, 2017 until April 15, 2019. Mr. Long is a seasoned finance executive with three decades of experience in the life sciences, bio-pharma and industrial sectors. His extensive skillset includes: corporate and operational finance, strategy, supply chain, information technology, M&A integration and talent acquisition and development. Mr. Long served as Senior Vice President of Patheon Inc from 2015 to 2017 and served as its and Global Business Controller. Prior to his role at Patheon, Mr. Long spent nine years providing management and financial operations expertise as Vice President of Global Finance for multiple divisions at Thermo Fisher Scientific. He previously spent five years directing global financial planning, reporting and analysis activities for the BioScience Division of Cambrex Corporation. Prior to joining Thermo Fisher, he served as vice president of worldwide finance and supply chain management at Cambrex Corporation, responsible for global financial planning, reporting and analysis for a division with 14 manufacturing and distribution sites across 10 countries. Previously, he served in a number of roles of increasing responsibility for companies including Eaton Corporation, Emerson Electric and Abbott Laboratories. Mr. Long holds Bachelor of Science from Indiana University and Master of Business Administration from the Kellogg Graduate School of Business, Northwestern University.

CEO Compensation
  • Insufficient data for Andy to compare compensation growth.
  • Andy's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure of the INSYS Therapeutics management team in years:

0.5
Average Tenure
  • The average tenure for the INSYS Therapeutics management team is less than 2 years, this suggests a new team.
Management Team

Steven Meyer

TITLE
Executive Chairman
COMPENSATION
$303K
AGE
61

Andy Long

TITLE
Chief Executive Officer
COMPENSATION
$1M

Franc Del Fosse

TITLE
Senior Vice President of Corporate Affairs
COMPENSATION
$1M
AGE
46
TENURE
0.5 yrs

Andrece Housley

TITLE
Chief Financial Officer

Venkat Goskonda

TITLE
Chief Scientific Officer

Mark Nance

TITLE
Chief Legal Officer & General Counsel
TENURE
0.5 yrs

Brian Jennings

TITLE
Vice President of Sales
TENURE
1.8 yrs
Board of Directors Tenure

Average tenure and age of the INSYS Therapeutics board of directors in years:

1.6
Average Tenure
61
Average Age
  • The average tenure for the INSYS Therapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors

Steven Meyer

TITLE
Executive Chairman
COMPENSATION
$303K
AGE
61
TENURE
2.3 yrs

Pierre Lapalme

TITLE
Independent Director
COMPENSATION
$248K
AGE
77
TENURE
8.1 yrs

Rana Vishnoi

TITLE
Independent Director
COMPENSATION
$238K
TENURE
1.9 yrs

Vaseem Mahboob

TITLE
Independent Director
AGE
49
TENURE
1.3 yrs

Trudy Vanhove

TITLE
Independent Director
TENURE
1 yrs

Elizabeth Bohlen

TITLE
Independent Director
TENURE
0.7 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
14. May 18 Sell Brian Tambi Individual 10. May 18 10. May 18 -4,000 €5.39 €-21,556
X
Management checks
We assess INSYS Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. INSYS Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

NPR1 News

Simply Wall St News

NPR1 Company Info

Description

Insys Therapeutics, Inc., a specialty pharmaceutical company, focuses on cannabinoids and drug delivery systems that address unmet patient needs. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. It also develops Cannabidiol Oral Solution, a synthetic cannabidiol, for the treatment of rare childhood epilepsy syndromes that include west syndrome and childhood absence epilepsy, as well as glioblastoma multiforme, pontine glioma, and pediatric schizophrenia. In addition, the company develops Buprenorphine Sublingual Spray for acute pain; Epinephrine Nasal Spray for allergic reactions, including anaphylaxis; and Naloxone Nasal Spray for opioid antagonist. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona.

Details
Name: INSYS Therapeutics, Inc.
NPR1
Exchange: DB
Founded:
$284,708,934
74,428,260
Website: http://www.insysrx.com
Address: INSYS Therapeutics, Inc.
1333 South Spectrum Boulevard,
Suite 100,
Chandler,
Arizona, 85286,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM INSY Common Stock Nasdaq Global Market US USD 10. Nov 2010
DB NPR1 Common Stock Deutsche Boerse AG DE EUR 10. Nov 2010
LSE 0JBS Common Stock London Stock Exchange GB USD 10. Nov 2010
Number of employees
Current staff
Staff numbers
226
INSYS Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 21:43
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/04
Last earnings filing: 2019/03/13
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.